Plus therapeutics granted u.s. fda orphan drug designation to rhenium (186re) obisbemeda for the treatment of breast cancer with leptomeningeal metastases

Austin, texas, nov. 03, 2023 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to rhenium (186re) obisbemeda for the treatment of breast cancer with leptomeningeal metastases (lm).
pstv Ratings Summary
pstv Quant Ranking